A practicing pathologist explains why DaVita, UnitedHealth, and Natera are playing fundamentally different games — and why one of them could break first.
Investing in healthcare stocks requires a different framework than semiconductor investing. In this excerpt from a CSI live Q&A, we sit down with Dr. Brad Gibson — a practicing pathologist and private-practice partner — to break down how the US healthcare system actually gets paid, and what that means for stock picking.
Brad walks through four investable buckets: medical service providers (DaVita, Natera, TransMedics), health insurers (UnitedHealth, CVS, Cigna, Elevance), pharmaceutical companies (Eli Lilly, Vertex), and healthcare hardware/software providers (Stryker, Veeva, Intuitive Surgical).
The conversation covers Medicaid and Medicare reimbursement mechanics, CPT codes and RVU conversion factors, why private practices are being pushed into hospital consolidation, how pharmacy benefit managers generate profit through rebates, and why UnitedHealthcare's vertical integration has drawn regulatory scrutiny. Brad also gives his take on AI in pathology and drug discovery, and explains why he's more concerned about a healthcare cost bubble than an AI bubble.
If you're building a healthcare investing thesis for 2026, this is where to start.
If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth: https://www.chipstockinvestor.com
All our socials: https://linktr.ee/chipstockinvestor
Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal.
